Brought to you by 
CardioDx brings in $57.5mm so far through its Series E round
12 May 2011
Executive Summary
CardioDx Inc. (cardiovascular diagnostics) has raised $57.5mm through its Series E venture round. New backer Longitude Capital led (and contributes a board member) and was joined by current shareholders Kleiner Perkins Caufield & Byers, TPG, MDV, Intel Capital, Pappas Ventures, DAG Ventures, Asset Management Group, GE Capital, and eight other undisclosed investors. According to CardioDx’s Form D filing, it may bring in another $20.8mm before closing the financing.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CardioDx brings in $57.5mm so far through its Series E round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice